Obesity and type 2 diabetes: which patients are at risk?

被引:71
|
作者
Garber, A. J. [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
diabetes complications; glucose metabolism; insulin resistance; treatment guidelines; type; 2; diabetes; weight-loss therapy; IMPAIRED GLUCOSE-TOLERANCE; FASTING GLUCOSE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; ADIPOSE-TISSUE; ECTOPIC FAT; WEIGHT-LOSS; PREVENTION PROGRAM; METABOLIC SYNDROME; RECEPTOR AGONISTS;
D O I
10.1111/j.1463-1326.2011.01536.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An estimated 72.5 million American adults are obese, and the growing US obesity epidemic is responsible for substantial increase in morbidity and mortality, as well as increased health care costs. Obesity results from a combination of personal and societal factors, but is often viewed as a character flaw rather than a medical condition. This leads to stigma and discrimination towards obese individuals and decreases the likelihood of effective intervention. Conditions related to obesity are increasingly common, such as metabolic syndrome, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), all of which indicate high risk for type 2 diabetes (T2DM). This paper reviews the progression from obesity to diabetes, identifying physiological changes that occur along this path as well as opportunities for patient identification and disease prevention. Patients with prediabetes (defined as having IFG, IGT or both) and/or metabolic syndrome require interventions designed to preserve insulin sensitivity and beta-cell function, both of which start to deteriorate prior to T2DM diagnosis. Lifestyle modification, including both healthy eating choices and increased physical activity, is essential for weight management and diabetes prevention. Although sustained weight loss is often considered by patients and physicians as being impossible to achieve, effective interventions do exist. Specifically, the Diabetes Prevention Program (DPP) and programs modelled along its parameters have shown repeated successes, even with long-term maintenance. Recent setbacks in the development of medications for weight loss further stress the importance of lifestyle management. By viewing obesity as a metabolic disorder rather than a personal weakness, we can work with patients to address this increasingly prevalent condition and improve long-term health outcomes.
引用
收藏
页码:399 / 408
页数:10
相关论文
共 50 条
  • [21] Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes
    Esser, Nathalie
    Legrand-Poels, Sylvie
    Piette, Jacques
    Scheen, Andre J.
    Paquot, Nicolas
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 105 (02) : 141 - 150
  • [22] Obesity and type 2 diabetes
    Waine, C.
    NUTRITION BULLETIN, 2006, 31 (02) : 111 - 114
  • [23] Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial
    Chuengsamarn, Somlak
    Rattanamongkolgul, Suthee
    Phonrat, Benjaluck
    Tungtrongchitr, Rungsunn
    Jirawatnotai, Siwanon
    JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2014, 25 (02) : 144 - 150
  • [24] Obesity and the Risk of Infertility, Gestational Diabetes, and Type 2 Diabetes in Polycystic Ovary Syndrome
    Pirotta, Stephanie
    Joham, Anju
    Grieger, Jessica A.
    Tay, Chau Tien
    Bahri-Khomami, Mahnaz
    Lujan, Marla
    Lim, Siew S.
    Moran, Lisa J.
    SEMINARS IN REPRODUCTIVE MEDICINE, 2020, 38 (06) : 342 - 351
  • [25] Does physical activity modify the risk of obesity for type 2 diabetes: a review of epidemiological data
    Qin, Li
    Knol, Mirjam J.
    Corpeleijn, Eva
    Stolk, Ronald P.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2010, 25 (01) : 5 - 12
  • [26] Waist circumference and metabolic risk factors have separate and additive effects on the risk of future Type 2 diabetes in patients with vascular diseases. A cohort study
    Wassink, A. M. J.
    van der Graaf, Y.
    van Haeften, T. W.
    Spiering, W.
    Soedamah-Muthu, S. S.
    Visseren, F. L. J.
    DIABETIC MEDICINE, 2011, 28 (08) : 932 - 940
  • [27] INFLAMMATION AS A FACTOR OF THE PATHOGENESIS OF INSULIN RESISTANCE AND TYPE 2 DIABETES
    Schwarz, V.
    TERAPEVTICHESKII ARKHIV, 2009, 81 (10) : 74 - 80
  • [28] Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD
    Reeves, Helen L.
    Zaki, Marco Y. W.
    Day, Christopher P.
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) : 1234 - 1245
  • [29] The Evidence for an Obesity Paradox in Type 2 Diabetes Mellitus
    Han, Seung Jin
    Boyko, Edward J.
    DIABETES & METABOLISM JOURNAL, 2018, 42 (03) : 179 - 187
  • [30] Myokines: metabolic regulation in obesity and type 2 diabetes
    Chen, Zhi-Tian
    Weng, Zhi-Xuan
    Lin, Jiandie D.
    Meng, Zhuo-Xian
    LIFE METABOLISM, 2024, 3 (03):